Zimmer Biomet Holdings $500M Debt Financing with Barclays Capital Inc.
Zimmer Biomet Holdings, Inc. completed a dual-currency public offering of senior notes, consisting of $500 million of 5.850% notes due 2036 and €500 million of 4.375% notes due 2033. The proceeds are intended to be used for general corporate purposes, which may include the repayment of existing 2.425% notes due 2026 and 4.700% notes due 2027.
For the nine months ended September 30, 2026, Zimmer Biomet reported net sales of $6,326.6 million, a 5.7% increase over the prior year, and net earnings of $630.9 million. The company experienced higher selling, general, and administrative expenses but saw an improvement in operating profit from $943.6 million to $1,006.8 million year-over-year.
Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, a 3.1% increase over the prior year, driven by strong performance in its Hips, S.E.T., and Technology & Data franchises. The company updated its full-year 2026 guidance, raising its organic constant-currency sales growth and adjusted EPS targets based on solid commercial execution.
Term
Q3 2026
“We are very pleased with our solid third quarter results, growing net sales 3.7% on a constant-currency basis and generating strong operating and free cash flow. Our Hips, S.E.T. and Technology & Data, Bone Cement and Surgical franchises – representing two-thirds of our book of business – grew at upper single digit or double-digit rates, validating the progress of our diversification strategy, the strength of our innovation engine and the significant strides we are making in commercial execution.”
Ivan Tornos, Chairman, President and CEO of Zimmer Biomet